

Gregor Hoermann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5924506/publications.pdf>

Version: 2024-02-01

127
papers

3,593
citations

147566

31
h-index

161609

54
g-index

129
all docs

129
docs citations

129
times ranked

6073
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. <i>European Respiratory Journal</i> , 2021, 57, 2003481.	3.1	313
2	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195
3	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. <i>Blood</i> , 2014, 123, 3951-3962.	0.6	189
4	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. <i>Blood</i> , 2011, 117, 3409-3420.	0.6	168
5	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
6	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	2.2	130
7	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	1.2	128
8	Hereditary β -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. <i>Blood</i> , 2021, 137, 238-247.	0.6	113
9	CDK8-Mediated STAT1-S727 Phosphorylation Restrains NK Cell Cytotoxicity and Tumor Surveillance. <i>Cell Reports</i> , 2013, 4, 437-444.	2.9	104
10	Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. <i>Blood</i> , 2008, 111, 2200-2210.	0.6	85
11	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. <i>Journal of Immunology</i> , 2008, 180, 5466-5476.	0.4	75
12	Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis. <i>PLoS ONE</i> , 2009, 4, e8292.	1.1	68
13	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011, 118, 1885-1898.	0.6	64
14	Delineation of target expression profiles in CD34 ⁺ /CD38 ^{hi} and CD34 ⁺ /CD38 ⁺ stem and progenitor cells in AML and CML. <i>Blood Advances</i> , 2020, 4, 5118-5132.	2.5	62
15	Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. <i>Leukemia Research</i> , 2017, 59, 47-54.	0.4	58
16	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph ⁺ CML. <i>Clinical Cancer Research</i> , 2016, 22, 2051-2061.	3.2	52
17	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 789.	1.8	50
18	Long-term treatment with imatinib results in profound mast cell deficiency in Ph ⁺ chronic myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 3071-3084.	0.8	50

#	ARTICLE	IF	CITATIONS
19	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	1.5	49
20	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1175-1183.	0.6	48
21	Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. <i>Blood</i> , 2015, 126, 2832-2841.	0.6	47
22	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400.	0.6	46
23	Identification of Basophils as a Major Source of Hepatocyte Growth Factor in Chronic Myeloid Leukemia: A Novel Mechanism of BCR-ABL1-Independent Disease Progression. <i>Neoplasia</i> , 2012, 14, 572-IN10.	2.3	45
24	Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML. <i>Blood</i> , 2013, 122, 257-257.	0.6	41
25	Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. <i>FASEB Journal</i> , 2012, 26, 894-906.	0.2	40
26	Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. <i>Mediators of Inflammation</i> , 2015, 2015, 1-17.	1.4	40
27	Frequent occurrence of T _H 2-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 601-609.e8.	1.5	37
28	Identification of Oncostatin M as a STAT5-Dependent Mediator of Bone Marrow Remodeling in KIT D816V-Positive Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2011, 178, 2344-2356.	1.9	36
29	Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation. <i>Scientific Reports</i> , 2017, 7, 42191.	1.6	36
30	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	1.7	36
31	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	2.0	35
32	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. <i>Nature Chemical Biology</i> , 2019, 15, 232-240.	3.9	34
33	The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. <i>Journal of Leukocyte Biology</i> , 2013, 95, 95-104.	1.5	32
34	Phenotyping and Target Expression Profiling of CD34 ⁺ /CD38 ^{low} and CD34 ⁺ /CD38 ⁺ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia. <i>Neoplasia</i> , 2018, 20, 632-642.	2.3	32
35	Expression of CD25 on leukemic stem cells in BCR-ABL1 ⁺ CML: Potential diagnostic value and functional implications. <i>Experimental Hematology</i> , 2017, 51, 17-24.	0.2	31
36	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	1.7	30

#	ARTICLE	IF	CITATIONS
37	A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9942-9951.	3.3	29
38	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	1.7	27
39	Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML. <i>Clinical Cancer Research</i> , 2014, 20, 3589-3602.	3.2	26
40	The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-12.	1.0	26
41	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	2.5	25
42	CD52 is a molecular target in advanced systemic mastocytosis. <i>FASEB Journal</i> , 2014, 28, 3540-3551.	0.2	24
43	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	0.6	24
44	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017, 26, 17-24.	2.7	24
45	The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils. <i>PLoS ONE</i> , 2012, 7, e29925.	1.1	24
46	Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2458.	1.8	23
47	The tryptophan metabolite picolinic acid suppresses proliferation and metabolic activity of CD4+ T cells and inhibits c-Myc activation. <i>Journal of Leukocyte Biology</i> , 2016, 99, 583-594.	1.5	22
48	Identification of a leukemia-initiating stem cell in human mast cell leukemia. <i>Leukemia</i> , 2019, 33, 2673-2684.	3.3	21
49	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	1.7	21
50	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411.	1.8	21
51	Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. <i>Annals of Hematology</i> , 2015, 94, 223-231.	0.8	20
52	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	2.0	20
53	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865.	1.5	19
54	Homozygous familial hypercholesterolemia: Summarized case reports. <i>Atherosclerosis</i> , 2017, 257, 86-89.	0.4	18

#	ARTICLE	IF	CITATIONS
55	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771.	1.7	18
56	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. <i>Blood</i> , 2018, 132, 1936-1950.	0.6	18
57	Lipoprotein(a) is not related to markers of insulin resistance in pregnancy. <i>Cardiovascular Diabetology</i> , 2013, 12, 138.	2.7	17
58	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (Iâ€•CBF) Tj ETQq 0 0 0 rgBT /Overlo	1.3	17
59	Thyroid and androgen receptor signaling are antagonized by Î¼4â€•Crystallin in prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 731-747.	2.3	17
60	Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1964-1973.	2.0	17
61	Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. <i>Experimental Hematology</i> , 2018, 57, 50-59.e6.	0.2	16
62	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	2.7	14
63	Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS. <i>Blood</i> , 2014, 124, 1570-1570.	0.6	14
64	<sc>BRD4</sc> degradation blocks expression of <sc>MYC</sc> and multiple forms of stem cell resistance in Ph⁺ chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1215-1225.	2.0	14
65	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072.	0.8	13
66	The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. <i>Oncotarget</i> , 2017, 8, 67709-67722.	0.8	13
67	FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H. <i>Leukemia Research Reports</i> , 2014, 3, 8-13.	0.2	12
68	Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology. <i>Journal of Personalized Medicine</i> , 2020, 10, 94.	1.1	12
69	STAT5 is Expressed in CD34+/CD38â€• Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
70	Transposon-mediated generation of <i>BCR-ABL1</i>-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. <i>Oncotarget</i> , 2016, 7, 78083-78094.	0.8	12
71	Expansion of <i>BCR</i>/<i>ABL</i>1⁺ cells requires <i>PAK</i>2 but not <i>PAK</i>1. <i>British Journal of Haematology</i> , 2017, 179, 229-241.	1.2	11
72	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. <i>HemaSphere</i> , 2021, 5, e536.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥ 60 years. <i>American Journal of Hematology</i> , 2017, 92, E567-E574.	2.0	9
74	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. <i>FASEB Journal</i> , 2021, 35, e21217.	0.2	9
75	Mast cells are not associated with systemic insulin resistance. <i>European Journal of Clinical Investigation</i> , 2016, 46, 911-919.	1.7	8
76	Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2761-2768.e16.	2.0	8
77	Monitoring Molecular Response, Minimal Residual Disease and Clonal Structures in Polycythemia Vera Patients Treated with Interferon Alpha. <i>Blood</i> , 2016, 128, 1944-1944.	0.6	8
78	A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition. <i>Frontiers in Pediatrics</i> , 2020, 8, 52.	0.9	7
79	Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinite growth in colon cancer cells. <i>American Journal of Cancer Research</i> , 2015, 5, 560-74.	1.4	7
80	Molecular imaging and molecular diagnostics: two sides of the same coin?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1645-1648.	3.3	6
81	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	0.7	6
82	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. <i>Blood</i> , 2007, 110, 1541-1541.	0.6	6
83	Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 817-817.	0.6	6
84	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. <i>Oncotarget</i> , 2016, 7, 12191-12205.	0.8	6
85	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	0.6	6
86	Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6057.	1.8	5
87	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. <i>Blood</i> , 2018, 132, 1722-1722.	0.6	5
88	Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome+ CML. <i>Blood</i> , 2014, 124, 1800-1800.	0.6	5
89	A Novel Fusion Gene NDEL1-Pdgfrb in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of PDGFRI ² . <i>Blood</i> , 2014, 124, 613-613.	0.6	5
90	DDRGI1 in urine indicative of tubular cell injury in intensive care patients with serious infections. <i>Journal of Nephropathology</i> , 2016, 5, 65-71.	0.1	5

#	ARTICLE	IF	CITATIONS
91	Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. <i>American Journal of Cancer Research</i> , 2015, 5, 354-62.	1.4	5
92	Cardio-pathogenic variants in unexplained intrauterine fetal death: a retrospective pilot study. <i>Scientific Reports</i> , 2021, 11, 6737.	1.6	4
93	LMO3 reprograms visceral adipocyte metabolism during obesity. <i>Journal of Molecular Medicine</i> , 2021, 99, 1151-1171.	1.7	4
94	Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential in Hematology and Cardiovascular Disease. <i>Diagnostics</i> , 2022, 12, 1613.	1.3	4
95	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.0	3
96	Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. <i>Cancers</i> , 2020, 12, 1891.	1.7	3
97	Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. <i>European Journal of Haematology</i> , 2021, 106, 627-633.	1.1	3
98	Interference of Mycoplasma Infection in a Gene Expression Study: It Was the Environment and Not the Gene. <i>Applied and Environmental Microbiology</i> , 2010, 76, 7867-7869.	1.4	2
99	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. <i>Blood</i> , 2018, 132, 1363-1363.	0.6	2
100	Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC. <i>Blood</i> , 2016, 128, 4234-4234.	0.6	2
101	Comparative Analysis of Japanese and European Typical CLL Patients. <i>Blood</i> , 2016, 128, 5564-5564.	0.6	2
102	Endogenous Erythroid Colony Formation in Chronic Myeloid Leukemia: A Recurrent Finding Associated with Persistent Minimal Residual Disease Under Imatinib. <i>Stem Cells and Development</i> , 2013, 22, 3043-3051.	1.1	1
103	Major response of PNH to an AML chemotherapy protocol. <i>Annals of Hematology</i> , 2018, 97, 1487-1488.	0.8	1
104	Comparison of <i>BCR-ABL1</i> quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1214-1222.	1.4	1
105	Cytomegalovirus in urinary sediment in patients with acute kidney injury. <i>BMC Nephrology</i> , 2021, 22, 169.	0.8	1
106	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4223-4223.	0.6	1
107	The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+/CD38 ^{low} /Lin ^{low} Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1 α . <i>Blood</i> , 2011, 118, 961-961.	0.6	1
108	Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms. <i>Blood</i> , 2013, 122, 3747-3747.	0.6	1

#	ARTICLE	IF	CITATIONS
109	Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis. Blood, 2013, 122, 3773-3773.	0.6	1
110	The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph+ CML. Blood, 2013, 122, 3979-3979.	0.6	1
111	Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml. Blood, 2016, 128, 4241-4241.	0.6	1
112	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. Neoplasia, 2021, 23, 1183-1191.	2.3	1
113	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. Memo - Magazine of European Medical Oncology, 2013, 6, 114-118.	0.3	0
114	Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration.. Blood, 2010, 116, 1202-1202.	0.6	0
115	Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis.. Blood, 2012, 120, 2866-2866.	0.6	0
116	KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease. Blood, 2013, 122, 4052-4052.	0.6	0
117	Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML. Blood, 2013, 122, 3988-3988.	0.6	0
118	Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML. Blood, 2014, 124, 4526-4526.	0.6	0
119	CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis. Blood, 2015, 126, 1635-1635.	0.6	0
120	Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells. Blood, 2016, 128, 5425-5425.	0.6	0
121	Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation. Blood, 2016, 128, 3189-3189.	0.6	0
122	High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis. Blood, 2016, 128, 5503-5503.	0.6	0
123	Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients. Blood, 2017, 130, 800-800.	0.6	0
124	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	0.6	0
125	Phenotyping of Disease-Initiating CD34+/CD38â”€ Stem Cells in BCR-ABL1â”€ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens. Blood, 2020, 136, 53-53.	0.6	0
126	PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.. American Journal of Cancer Research, 2021, 11, 6042-6059.	1.4	0

#	ARTICLE	IF	CITATIONS
127	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. <i>Cancers</i> , 2022, 14, 3070.	1.7	0